SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q2 2026 · 67 positions · Total reported value $855.33M · Top-10 concentration 47.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 67 equity positions with a combined reported value of $855.33M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ASND ($55.01M), CELC ($52.41M), COGT ($49.56M). By sector, the heaviest allocations are Health Care 98.1%, Financials 1.9%. Versus the prior quarter, allocation shifted toward Health Care (+13.6pp) and away from Other (-14.0pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 55% of names.

The largest new positions opened in Q2 2026 were ELVN ($24.84M), SGMT ($22.63M), DFTX ($18.82M).

Of the 18 positions fully exited versus the prior quarter, the largest were KALV ($57.90M), NUVL ($36.36M), CNTA ($18.52M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ELVN ENLIVEN THERAPEUTICS INC · $24.84M
  • SGMT SAGIMET BIOSCIENCES INC · $22.63M
  • DFTX DEFINIUM THERAPEUTICS INC · $18.82M
  • ALXO ALX ONCOLOGY HLDGS INC · $11.89M
  • MANE VERADERMICS INC · $11.68M
  • AVLN AVALYN PHARMACEUTICALS INC · $10.88M
  • ACRS ACLARIS THERAPEUTICS INC · $10.30M
  • AVTX AVALO THERAPEUTICS INC · $9.25M

Fully Exited (vs previous quarter)

  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $57.90M
  • NUVL NUVALENT INC · prev qtr: $36.36M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $18.52M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $16.70M
  • CGON CG ONCOLOGY INC · prev qtr: $11.26M
  • CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $5.66M · history
  • CYTK CYTOKINETICS INC · prev qtr: $4.69M
  • CLYM CLIMB BIO INC · prev qtr: $4.69M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.1%
Financials 1.9%
Other 0.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 206.23K $55.01M 6.43%
6.43%
Add
2 501.00K $52.41M 6.13%
6.13%
Add
3 1.28M $49.56M 5.79%
5.79%
Reduce
4 1.30M $47.91M 5.60%
5.60%
Reduce
5 2.02M $42.74M 5.00%
5.00%
Add
6 390.00K $38.02M 4.45%
4.45%
Reduce
7 311.46K $34.58M 4.04%
4.04%
Add
8 352.80K $33.58M 3.93%
3.93%
Add
9 489.38K $24.84M 2.90%
2.90%
New
10 619.10K $23.85M 2.79%
2.79%
Add
11 1.26M $23.14M 2.71%
2.71%
Reduce
12 2.93M $22.63M 2.65%
2.65%
New
13 65.68K $21.99M 2.57%
2.57%
Reduce
14 546.26K $21.28M 2.49%
2.49%
Reduce
15 400.00K $18.82M 2.20%
2.20%
New
16 318.00K $18.68M 2.18%
2.18%
Add
17 693.60K $15.16M 1.77%
1.77%
Add
18 99.83K $14.98M 1.75%
1.75%
Add
19 3.03M $14.16M 1.66%
1.66%
Add
20 509.79K $12.94M 1.51%
1.51%
Reduce
21 678.10K $12.65M 1.48%
1.48%
Add
22 1.18M $12.53M 1.47%
1.47%
Reduce
23 5.74M $11.89M 1.39%
1.39%
New
24 95.00K $11.68M 1.36%
1.36%
New
25 186.82K $11.28M 1.32%
1.32%
Reduce
26 330.49K $10.88M 1.27%
1.27%
New
27 48.10K $10.39M 1.22%
1.22%
Reduce
28 1.95M $10.30M 1.20%
1.20%
New
29 3.47M $10.14M 1.19%
1.19%
Add
30 500.40K $9.25M 1.08%
1.08%
New
31 679.83K $9.10M 1.06%
1.06%
Reduce
32 145.00K $8.43M 0.98%
0.98%
Hold
33 122.27K $8.39M 0.98%
0.98%
New
34 1.36M $8.35M 0.98%
0.98%
Reduce
35 3.10M $8.34M 0.97%
0.97%
Add
36 682.60K $7.39M 0.86%
0.86%
Reduce
37 300.00K $7.26M 0.85%
0.85%
Reduce
38 503.38K $7.12M 0.83%
0.83%
Add
39 3.18M $6.81M 0.80%
0.80%
Reduce
40 668.45K $6.68M 0.78%
0.78%
New
41 50.00K $6.66M 0.78%
0.78%
Reduce
42 3.52M $6.16M 0.72%
0.72%
Add
43 82.80K $6.06M 0.71%
0.71%
Reduce
44 113.49K $5.95M 0.69%
0.69%
Reduce
45 59.96K $5.32M 0.62%
0.62%
Reduce
46 525.00K $5.09M 0.59%
0.59%
New
47 296.13K $4.85M 0.57%
0.57%
Reduce
48 105.00K $4.84M 0.56%
0.56%
Reduce
49 360.00K $3.85M 0.45%
0.45%
New
50 610.41K $3.77M 0.44%
0.44%
Reduce

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 67 equity positions worth $855.33M in aggregate; its largest disclosed positions were ASND ($55.01M), CELC ($52.41M), COGT ($49.56M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $855.33M of long equity holdings across 67 positions as of 2026-Q2. Top-10 holdings account for 47.1% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →